Clinical Trial Update: Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating the combination of subcutaneous blinatumomab and olverembatinib for Philadelphia chromosome-positive and/or BCR-ABL1-positive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)
• Olverembatinib (Olverembatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Phase II Clinical Trial, Blinatumomab | Phase 2 | Status: NOT_YET_RECRUITING